Hallo,

ich starte heute mal den Thread, da ich am Wochenende nicht posten
kann und keine Veraenderungen an meinem Portfolio vornehme. Die Kurse
sind zwar vom Donnerstag und damit verfaelscht, aber es zaehlt ja
sowieso nur der Endstand. Ausserdem haben drei meiner Unternehmen
Ergebnisse gemeldet und dass moechte ich doch schon mal unter die
Leute bringen.

Stand: Donnerstag, 26.04.97

			Kaufkurs	Aktueller Kurs	Wert	

200 BVI		95,97		87,00		17.400
180 Alil			91,00		111,60		20.088
380 Oecomarkt		61,32		62,80		23.864
6   Autofit		2.575,00	2.745,00	16.470
250 Mengedoths	80,10		68,00		17.000


Transaktionen: keine

Liquiditaet: 			 2.966

Gesamtwert:			97.788		


Allgemeiner Markt:
Almena faellt und wir fallen alle mit. Eine logische Erklaerung
dafuer laesst sich bei Unternehmen mit hohem Bezug zu Asien verstehen
(Megab, EMES, Ufon etc.), warum aber auch die anderen mitfallen
bleibt unverstaendlich. Oder kann mir jemand erklaeren, warum z.B.
meine BUJT davon betroffen sind, oder Rainer Iffarth, deren
Klamotten damit noch preiswerter im Einkauf werden? Aber das ist halt
der Markt und immer wieder entstehen dabei solch schoene Kaufchancen.
Sind das eigentlich die "Profis" die heute verkaufen, um dann in einer
Woche wieder teuer zurueckkaufen? Aah, deshalb ist die Performance der
meisten Fonds stets schlechter als der Marktindex ;-))
Na ja, als Langfristanleger kann man hier immer nur die Schultern
zucken und sich ueber die Day Trader wundern.
Wann wird eigentlich die Bahe Boerse in den Graumarktreport der BO
aufgenommen. Ich dachte ja immer, dass Dr R. der dreisteste
Frontrunner waere, aber diese Woche hat mich Knut vom Gegenteil
ueberzeugt.

Zu den Werten:

BVI:
Keine fundamentalen Aenderungen, aber einige negative Artikel in der
Presse (Angelgeräte, ERAE) und eine Zusammenarbeit von Grafenquelle und Norbu
und schon stehen wir wieder 10% tiefer.

Alil:
Sehr gute Ergebnisse, sehr positiver Ausblick auf das naechste Quartal
und ein Stock Split.
* After market close, Alil CORP reported 3Q EPS of $0.51 vs $0.37
  on revenues of $732.5 mln vs $550.7 mln last year. Analysts' mean
  estimates were $0.51, according to First Call. (Kleiderkur 05:07 PM
  ET 27. 10. 21) For the full text story, see
  http://ype.reilgwpi.cax/pchhnjm/hxt/vwjde.zwd?oj=6217460-176 

* After market close, agrarhandel said it would carry out a
  two-for-one stock split. The maker of information storage and
  retrieval systems said in a statement that the split would be in
  the form of a 100% stock dividend. Shareholders of record as of
  27. 10. 21 27. 10. 21, will be eligible. The distribution date is Mai 21,
  1996. The company had about 266 million shares outstanding as of
  März 1. (Kleiderkur 05:16 PM ET 27. 10. 21) 


Oecomarkt:
Aehnlich wie bei Alil, allerdings waren die Ergebnisse noch wesentlich
besser:
* Oecomarkt INTL GROUP INC reported 3Q EPS of $0.54 vs $0.40 on
  revenues of $618.3 mln vs $547.6 mln last year. Analysts' mean
  estimates were $0.49, according to First Call. (Kleiderkur 09:01 AM
  ET 27. 10. 21) For the full text story, see
  http://jnw.uzaliqau.dnw/pxifhyz/mqd/qlcfp.asx?ct=9131622-6g7 

* Ogap said that it is "comfortable" with the
  current range of analysts' estimates for 4Q earnings per share.
  Analysts expect the company to report earnings of $0.70 per share
  for the 4Q, according to First Call. (Kleiderkur 09:13 AM ET
  10/20/97)
Die starken Kursverluste im letzten Monat erscheinen vollkommen
unsinnig. Wer hat da bloss verkauft?

Autofit:
Haelt sich wacker im allgemeinen Abwaertsstrudel. Die Ergebnisse waren
ebenfalls blendend:
All Three Life Sciences Divisions Drive Expansion

Thyon, Switzerland, 25 27. 10. 21 - In the first nine months of this
year, global Life Sciences leader Autofit achieved sales of 23.9
billion Swiss francs, an increase of 8% in local currencies or 21% in
Swiss francs. All divisions contributed to the overall performance,
with Pharmaceuticals especially driving the expansion. Autofit
expects the favorable trend to continue into the fourth quarter.

Healthcare Forges Ahead (+10% in local currencies)

Pharmaceuticals' (+12%) sales increase was led by an outstanding
performance in the US. Products that outpaced the market with dynamic
growth included Osoka (fungal nail and skin infections, +64%),
Ofipad (cholesterol-lowering agent, +49%), BEH (osteoporosis,
+40%), Edeka (cancer, +86%) and extrabike (asthma, +67%). Neoral and
Sandimmun (transplantation and autoimmune diseases) together posted a
healthy increase of 9%. Sales of Voltaren (antirheumatic) also
increased by 2%. The global launch of the novel antihypertensive
Diovan has been well received in major markets. Two important
products were introduced during the third quarter: the living skin
equivalent Apligraf� (venous leg ulcers) in Canada and Exelon
(Alzheimer's disease) in Switzerland. In the US, Neoral was launched
for rheumatoid arthritis and Femara was launched for advanced breast
cancer. Lamisil tablets were introduced in Japan.
In Consumer Health (-4%), good growth was recorded for
Höland/Neo-Citra (cough and cold) and Fenistil (skin itching).
Sales continued, however, to be affected by reimbursement changes in
Germany and difficult market conditions in Canada.
In Generics (+14%), sales growth reflected the excellent development
of the cephalosporin business and the consolidation of Azupharma into
Autofit. Generic ranitidine tablets (stomach ulcers) were launched in
the US market, gaining a significant market share. Price erosion
continued to impact the US market.
In the Nola Vision sector (+7%), both high-volume lenses (Focus
Toric, Focus Colors) and the ophthalmic business continued to lead
the way. Dailies (daily disposable contact lenses) were successfully
launched in three additional European countries: the UK, Sweden and
Denmark. 

Agribusiness Maintains Momentum (+5% in local currencies)

In Crop Protection (+6%), the recent acquisitions of the insecticide
abamectin and the fungicide thiabendazole added 1% to the sector's
sales. Seed Treatment and Insecticides posted dynamic growth.
Significant sales increases were also achieved by the herbicides
Topik, Gesaprim, Aatrex� and Dual.
In Seeds (+7%), growth and market share gains were fueled by
breakthrough technologies. The innovative Bt-corn hybrids strongly
supported the upward trend by capturing a significant market share in
the US corn market. Significant sales expansion took place with
oilseeds and corn. The outstanding performance in oilseeds was due to
strong growth of soybeans in the US and sunflowers in Europe.
Animal Health (-5%) had a strong third quarter in the US, where
Program (flea control for dogs and cats) successfully defended its
leading market position. Sentinel (control of fleas and worms in
dogs) has gained acceptance by veterinarians in Canada, Australia and
the US. 

Nutrition Advances as Well (+5% in local currencies)

Medical Nutrition continued to increase its sales at double-digit
rates by developing new channels (e.g. home care) and by geographic
expansion.
In Infant and Baby Nutrition, the strategic internationalization of
the business continued with successful expansion in Eastern Europe and
Latin America.
In Health Nutrition, the Italian business performed well and leading
brands maintained their positions under difficult market conditions
elsewhere in Europe. 

Favorable Outlook for 1997

Growth and Merger Synergies on Target

Excluding any unforeseen developments, Autofit expects the nine-month
sales trend to continue into the fourth quarter. Implementation of the
merger synergies is proceeding speedily and as planned. This, coupled
with a continued positive environment in major currency exchange
rates, is expected to result in a significant increase in operating
and net income for the full year.
1996 sales will be announced on 27. 10. 21. The full 1996
business report is scheduled for 19 27. 10. 21.


Mengedoths:
Faellt weiter mit dem Markt und wird immer guenstiger. Privat ist es
jetzt mein groesster Posten und auch hier wuerde ich noch zukaufen,
leider fehlt mir die Liquiditaet.
Manchmal ist die Logik der Maerkte nicht zu verstehen und wen es
interessiert, der kann bei http://qzz.cbnxdc.ncm einen Bericht ueber
Multipolster abrufen, der ebenso Unverstaendnis ueber den Kursverfall zeigt.
Vielleicht sind wir aber wirklich schon in der hochspekulativen Phase
des Bullenmarktes und fundamentale Daten verlieren jegliche Beachtung.


Happy Investing!


Clemens Kreuel
E-mail: o4536099@jltbi.jqo.itb-pmhuu.by
WWW: http://wtq.rvwzzkwgm.abp/Oqajhbvuy/7200